Abbott Laboratories (ABT.N)
54.12USD
22 Dec 2009
$0.20 (+0.37%)
$53.92
$54.10
$54.29
$54.02
1,349,800
5,701,499
$57.39
$41.27
ABT.N
About
Overall
| Beta: | 0.19 |
| Market Cap (Mil.): | $83,400.13 |
| Shares Outstanding (Mil.): | 1,546.74 |
| Annual Dividend: | 1.60 |
| Yield (%): | 2.97 |
Financials
| ABT.N | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | 14.99 | 3.57 | 4.64 |
| EPS (TTM): | 23.36 | -- | -- |
| ROI: | 16.11 | 1.79 | 2.82 |
| ROE: | 27.52 | 2.40 | 3.58 |
'Good' cholesterol less protective with diabetes
CHICAGO, Dec 22 (Reuters) - Diabetes may lower the heart-protective benefits of high-density lipoprotein, or HDL, the so-called "good" cholesterol, but giving diabetics niacin, a drug that raises HDL levels, might restore the benefit, researchers said on Tuesday.
UPDATE 3-US FDA: unlikely Merck's Vytorin ups cancer risk
* No cancer risk seen in early results of 2 large studies
EU mergers and takeovers (Dec 21)
BRUSSELS, Dec 21 (Reuters) - The following are planned mergers under review by the European Commission and a brief guide to the EU merger process:
CORRECTED - UPDATE 1-Celgene psoriasis drug shows promise in trial
(Corrects ninth paragraph of Dec. 15 story to show Stelara targets interleukin proteins, not TNF)
UPDATE 2-US warns Abbott unit on problems at Swedish plant
* Cites issues at Advanced Medical Optics plant in Sweden
UPDATE 1-Celgene psoriasis drug shows promise in trial
* J.P. Morgan analyst sees potential sales of $500 million
US STOCKS-Futures slip on strong dollar; data on tap
* Futures lower: S&P 3.3 pts, Dow 20 pts, Nasdaq 5.5 pts
US STOCKS-Futures slip after gains, data on tap
* Futures lower: S&P by 3 pts, Dow 29 pts, Nasdaq 5.25 pts
U.S. stock futures signal weaker open; data eyed
* Futures for the Dow Jones industrial average , the S&P 500 and the Nasdaq 100 were down 0.2 to 0.3 percent at 1006 GMT, pointing to a weaker start on Wall Street on Tuesday.
AFTER THE BELL-Abbott Labs to buy Starlims; shares surge
NEW YORK, Dec 14 (Reuters) - Starlims Technologies Ltd shares surged 41.6 percent in extended trade on Monday after the company agreed to be acquired by Abbott Laboratories for about $123 million. [ID:nWNBB1098] (Reporting by Chuck Mikolajczak; Editing by Dan Grebler)
Competitors
| Price | Change | |
|---|---|---|
| Johnson & Johnson (JNJ.N) | $64.53 | +0.20 |
| Pfizer Inc. (PFE.N) | $18.61 | 0.00 |
| GlaxoSmithKline plc (GSK.L) | £1,326.00 | +25.00 |
| Novartis AG (NOVN.VX) | CHF56.85 | +0.60 |
| Bayer AG (BAYGn.DE) | €55.43 | -0.29 |
| Bayer AG (BAYE.F) | -- | -- |
| AstraZeneca plc (AZN.L) | £2,889.00 | +52.00 |
| Eli Lilly & Co. (LLY.N) | $36.11 | -0.13 |
| Wyeth (WYE.N) | -- | -- |
| Wyeth (WYE_p.N) | -- | -- |
Earnings vs 
Estimates
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
